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Background: To evaluate the feasibility and efficacy of Stereotactic body radiation therapy (SBRT) for primary liver
lesions and liver metastases treated with linear accelerators with or without rotational Intensity Modulated
RadioTherapy (IMRT).
Methods: Patients with either hepatocellular carcinoma, cholangiocarcinoma or metastatic liver lesions who had
one to three lesions treated with SBRT in a single institution were retrospectively reviewed. Tumor response was
evaluated according to EASL criteria 3 months after SBRT completion using MRI and/or abdominal CT scan.
Responses were categorised as: Stable Disease (SD), Partial Response (PR), Complete Response (CR), Local
Progression or Distant Progression in cases of new intra-hepatic lesions out-of-field or extra-hepatic metastases.
Local Control (LC), Progression Free Survival (PFS), Overall Survival (OS) and treatment-related toxicities are reported.
Results: Between 2007 and 2012, 20 patients with a total of 24 lesions were treated with SBRT. Fourteen patients
presented hepatocellular carcinoma (HCC), the others had either metastatic lesions from colorectal cancer (CRC) or
cholangiocarcinoma. The median diameter of the lesions was 23 mm (5–98).
The dose per fraction ranged from 6 to 20 Gy with a median total dose of 60 Gy (range: 36–60 Gy). The dose was
prescribed to the 80% isodose line covering the PTV.
The median follow-up was 24 months (15.7-29.7).
The actuarial LC rate was 78% for patients with HCC and 83% for those with adenocarcinoma and
cholangiocarcinoma. Median OS was 37 months and OS rates were 83% at 12 and 24 months for HCC and 100%
for adenocarcinoma. PFS was 54% for HCC and 50% for other types of tumors at 24 months.
Acute grade 3–4 toxicities occurred in 2 patients; a small proportion of the other patients experienced grade 1 or 2
toxicities.
Conclusions: SBRT provides excellent local control with minimal side effects in selected patients.
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HCC is the fourth most common cancer in the world
and SBRT offers an interesting alternative to invasive
management. Even though surgical resection remains
the gold standard in the management of primary or
metastatic liver disease, SBRT appears to be a treatment* Correspondence: pmaingon@cgfl.fr
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reproduction in any medium, provided the oroption for selected patients who are not eligible for sur-
gery or invasive procedures [1,2]. Invasive procedures
can provide comparable rates of long-term overall sur-
vival (OS), but pre-existing hepatic dysfunction, lesion
size or tumor site can significantly limit these modalities
with regard to patient eligibility and treatment side
effects.
Besides, as the liver is a common site of metastases of
many tumor types, patients with inoperable metastases
should be considered for SBRT in order to improve localral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Characteristics of patients and treatments
Sex Male = 19
Female = 1
Age (years) Median = 73 Range = 50-85
Time between diagnosis
and SBRT
Median = 5 months Range = 1.25-32.8
Follow-up 24 months Range = 16-30
Tumor diameter Median = 23 mm Range = 5-98 mm
Margins Median = 5 mm Range = 0-10 mm
Median PTV Dose Median = 60 Gy Range = 36-60 Gy
ITV Volume Median = 36 cc Range = 5-456 cc
PTV Volume Median = 95 cc Range = 5-1059 cc
D700cc Liver-PTV Mean = 14 Gy Range = 1-56 Gy
Dmean Liver-PTV Mean = 16 Gy Range = 2-80 Gy
PTV Volume/Liver-PTV Median = 0.06 Range = 0-1.64
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may be appropriate for selected patients suffering from «
oligo-metastatic » disease while a few high dose fractions
can provide local control rates higher than 70 to 80%,
which may improve survival and quality of life [3-5].
The aim of this retrospective study was to evaluate the
feasibility, features, tolerance and preliminary results
obtained in a non-selected series of patients treated with
SBRT delivered with or without rotational IMRT.
Methods
Between March 2007 and August 2012, a total of 24
lesions in 20 consecutive patients were treated with
SBRT and reviewed after approval from the Institutional
review Board of the Georges François Leclerc Cancer
Center. Informed consent (written or oral) was obtained
from all patients in accordance with national laws.
Fourteen patients suffered from HCC, four from liver
metastases from colorectal cancer and two patients
from cholangiocarcinoma. Adult patients with one to
three hepatic lesions were eligible and included (Table 1).
In most cases, the diagnosis of HCC was based on charac-
teristic images on Magnetic Resonance Imaging (MRI)
and high levels of alpha-foeto protein. Pathological con-
firmation was not required as long as established radio-
graphic criteria were satisfied. These patients often had
a previous but stable history of cirrhosis (11/14 HCC
patients). All of them were Child-Turcotte-Plugh A
during the treatment. All patients treated for metastatic
lesions were evaluated with both MRI and PET-TDM.













Patients were immobilized during CT simulation
using a customized, external vacuum-type
synthetic body mold from the neck to the pelvis.
To account for tumor motion during thee 1 Disease characteristics
ine characteristics of disease
number of patients 20
number of lesions evaluated 24
ry tumor: HCC 14 (70%)
ry tumor: CRC 4 (20%)
ry tumor: Cholangiocarcinoma 2 (10%)
um lesion diameter and range 23,5 mm
(12-98 mm)
ts with one liver lesion 13 (65%)
ts with two liver lesions 5 (25%)
ts with three liver lesions 2 (10%)
HepatoCellular Carcinoma, CRC = Colorectal Cancer.respiratory cycle, a Real-time Position
Management (RPM, Varian Medical Systems, Palo
Alto, CA) technique was chosen. As the patient is
scanned, the respiration signal is simultaneously
recorded. Once the images are acquired, they are
post-processed into individual 3D image sets
according to the respiratory phases. Patients were
prepared to maintain regular breathing using
audio breathing-training techniques.
2. Target definition
Because of the fast tumor wash-out of HCC, the
contrast information provided by 4D CT scan is
not accurate enough to delineate the target. We
therefore fused CT images with recent MRI by
using a rigid fusion procedure with four
corresponding points on liver anatomical
structures. Fiducials [2,3] already placed around
the target contributed to the accuracy of the
fusion process. The Gross Target Volume (GTV)
was delineated on a contrast-enhanced treatment
planning computed-tomography (CT) scan. It
included the tumor in all phases of the normal
respiratory cycle without respiratory gating or the
tumor-tracking system. To delineate the Internal
Target Volume (ITV), the GTV was expanded
manually using data provided by the 4D CT scan
showing fiducials motion and tumor position in
different phases of the respiratory cycle. A
median margin of 5 mm was added to the ITV to
obtain the Planning Target Volume (PTV).
3. Dosimetry planning, prescription dose and
treatment delivery
SBRT was planned and administered using
dynamic conformal arcs or multiple fixed
coplanar or non-coplanar fields generated by a
linear-accelerator with energies of 6 to 18 MV.
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according to the tumor location. Considering
stereotactic approach the dose prescription used
the 80% isodose prescription line currently
proposed in this setting. The dose per fraction
and total dose were determined using the Dose
Volume Histogram (DVH) and Organ At Risk
(OAR) with a schedule of 36 to 60 Gy in 6 to
15 Gy per fraction. The normal liver was defined
as the volume of liver not included in the PTV
(Liver-PTV) and the dose-constraints protocol
for normal liver specified that a minimum volume
of 700 cc should receive a total dose less than
15 Gy. Daily image guidance using on-board
cone-beam CT (CBCT) imaging was used to
relocalize the target before each treatment
delivery. No gating or tracking procedures have
been used during treatment delivery. Follow-up and evaluation of response
Acute toxicities were scored clinically once a week
during treatment, then monthly and then three
months after completion of the treatment. A clinical
examination and a biological work up combined with
a 3Tesla MRI or Abdominal CT scan were planned
3 months after radiation therapy and every
subsequent 3 months for 2 years. Late toxicities were
scored using the Common Terminology Criteria for
Adverse Events scoring system (CTCAE v4.0).
The response for each treated lesion was evaluated
using EASL criteria. Complete response (CR) was
defined as the absence of enhanced tumor area
reflecting complete tissue necrosis. Partial response
(PR) was a decrease greater than 50% of enhanced
areas (partial tissue necrosis). Progressive disease (PD)
was an increase greater than 25% in the size of at least
one measurable irradiated lesion. Stable disease
corresponded to a response between PD and PR.
 Study endpoints and statistics
The primary endpoint was Local Control (LC). New
or progressive lesions that developed within or at
the margin of the PTV were scored as in-field local
progression whereas lesions that developed outside
the PTV were scored as distant progression inside
or outside the liver. A lesion that developed in field
but after 6 months of follow-up was termed local
relapse. Secondary endpoints were toxicities,
Progression-Free Survival (PFS) and Overall Survival
(OS). Actuarial LC and OS curves were generated
using the Kaplan-Meier method.Figure 1 Local control.Results
20 consecutive patients with 24 liver lesions were
treated with SBRT and reviewed. The median follow-upwas 24 months. Fourteen lesions were treated with con-
ventional conformal radiotherapy and 10 lesions with
volumetric-modulated arctherapy. Among these 24 le-
sions, imaging studies showed a Complete Response (CR)
in 10 patients, a Partial Response (PR) in 4 patients, and
Stable Disease (SD) in 2 patients. The actuarial Local
Control (LC) of the irradiated lesions at 12 months was
78% for HCC patients and 83% for the others (Figure 1).
Of the responding patients, one subsequently developed
in-field progression. This was recorded as recurrence or
local relapse after CR. Four patients (21%) developed
lesions in the liver but outside the radiotherapy field.
Median OS was 37 months and actuarial OS by primary
tumor site is shown in Figure 2. Progression-Free Survival
(PFS) was 71% at 6 months and 53% at 24 months for
HCC (Figure 3). For metastatic adenocarcinoma, it was
50% at 6 months (Figure 3).Post-SBRT treatment
Six patients with an initial partial response had, for local
relapse or limited intra-hepatic progression 6 months
after SBRT, chemo-embolization (three patients), radio-
frequency ablation (RFA) (one patient), arterial chemo-
therapy (one patient) or surgery (one patient). Patients
Figure 2 Overall survival.
Figure 3 Progression free survival.
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or supportive care.
Toxicities
The most common side effects were abdominal pain and
nausea. Grade 1 or 2 toxicities occurred in 12 patients.
Two patients experienced Grade 3 or more toxicity. The
first one, with no history of cirrhosis, was treated for a
large lesion (98 mm). Three months after completion of
SBRT, he developed lethal Radiation Induced Liver Dis-
ease (RILD). D700cc was about 18 Gy. The second pa-
tient suffered from bleeding that required embolization.
He was treated for a 6-cm diameter biopsy-proven HCC.
D700cc was 11 Gy, D2cc to the stomach was 69.5 Gy.
Initial complete response was recorded 6 months after
completion of the radiotherapy. The patient died 8 months
later from gastric bleeding. Both patients had been taking
long-term bloodthinners for cardiovascular disorders. In
our study, the median maximal dose delivered to the heart
was 9.5 Gy without subsequent toxicity. There were nospinal cord or kidney toxicities. The maximum doses
to the chest wall ranged from 15.8 Gy to 27.7 Gy, and
there were no cases of pain or other complications
such as rib fracture.Discussion
SBRT is emerging as a new non-invasive approach for
local ablation in selected patients especially in patients
with either liver-confined metastatic disease [6,7] or pri-
mary liver carcinoma [8]. Phase I investigations now
suggest that SBRT can also be safely used to treat HCC in
cirrhotic patients with Child-Turcotte-Plugh (CTP) classes
A and B. Andolino et al. provided further support for the
safety and efficacy of SBRT for HCC for patients with a
CTP score ≤ 7 in a curative intent or as a bridge to trans-
plant [1]. Some studies have confirmed the efficacy and
safety of SBRT for metastatic lesions in an otherwise
healthy liver [9,10].
In the definition of SBRT proposed by Timmerman,
secure immobilization was the first point to ensure






Herfarth et al. [10] 12 Gy to 30% V12≤ 30%
7 Gy to 50% V7 ≤ 50%
Shefter et al. [18] 700 cc < 15 Gy V15≥ 700 cc
Kavanagh et al. [6]
Hoyer et al. [7] 10 Gy total < 30% V10 < 30%
Mendez Romero et al. [17] D33 < 21 Gy V < 21≤ 33%
D50 < 15 Gy V15≤ 50%
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devices [11]. In Case’s study, during free-breathing, the
average amplitude of liver motion was 1.4 mm in the
medial-lateral plane, 9.0 mm in the cranial-caudal plane
and 5.1 mm in antero-posterior plane [12]. Inter and
intra-fraction variability in liver position in non-breath-
hold SBRT lead to geometric uncertainties of no greater
than 1 centimeter in the cranial-caudal plane and 0.5 cm
in the axial plane. In our study, the ITV was recorded
during the breathing cycle and the accuracy of the repo-
sitioning was ensured using CBCT before each fraction
was delivered. Nonetheless, a 5 mm margin was applied
around the ITV to create the PTV according to the
pre-treatment evaluation of tumor motion on the 4D
CT-scan.
RapidArc (RA) is a Volumetric Modulated Arc Therapy
(VMAT) technique based on simultaneous optimisation of
Multi Leaf Collimator (MLC) shapes, dose rate and gantry
rotation speed. While the treatment dose is optimized and
calculated on a static CT image, the motion of the target
and the MLC may result in the delivered dose deviating
from the planned dose.
Some authors have highlighted this issue and the dosi-
metric impact of leaf interplay with breathing-induced
tumor motion. The reported differences were not signifi-
cant when RA was delivered with two different arcs and
within a single fraction plan [13]. One study concluded
that the interplay between the motion of both the leaves
and the target might induce an error in the delivered
dose [14]. In our experience, in order to avoid such
uncertainties in dose distribution, RA was not indicated
for tumors located in the interface between the liver and
the lung.
After the early experience of the University of Heidelberg
of single-fraction SBRT for liver metastases updated in
2005, they reported 18-month LC rate of 66% following
22 Gy in one fraction [10]. On the basis of the relationship
between LC and survival in surgical series and the
observed dose–response with SBRT, Rusthoven et al.
initiated a phase I/II multi-institutional trial of SBRT
for liver metastases to evaluate the safety and efficacy
of high dose SBRT [9]. Patients with one to three lesions
were included and treated with a total dose ranging from
36 to 60 Gy in a phase I dose-escalation trial. The phase II
dose was 60 Gy in 3 fractions and they demonstrated the
feasibility and efficacy of high-dose SBRT with a few
high-grade toxicities and high rates of LC. In our study,
14 patients received a total dose of 60 Gy: 9 in 4 fractions
and 5 in 3 fractions; toxicities were low-grade.
In the setting of HCC, Andolino et al. [1] compared
their results (with a median total dose between 40 and
44 Gy) with those reported by Tse et al. (median dose:
36 Gy) [15]. The former reported a LC rate of 90% at
2 years, while the latter reported an LC of 65% at 1 year.The most likely explanation could be a higher median
dose per fraction and a lower median tumor volume.
Emerging new technologies that allow partial volume
irradiation have lead us to reconsider the treatment of
liver tumors by irradiation. Sawrie et al. proposed a
review of normal tissue tolerance and toxicity in SBRT
for liver metastases and primary HCC [16]. Each regimen
provided a constraint to roughly one third of normal liver
tissue and across all studies, threshold doses ranged from
7 to 21 Gy. Studies by Mendez Romero et al. [17] and
Shefter et al. [18] were done with a critical volume con-
straint of 700 cc of normal liver that should not receive
more than 15 Gy, assuming that the liver volume was at
least 2,000 cc. Our data are consistent with other pub-
lished data on SBRT while using similar constraints to the
normal liver, acute and late liver toxicities were minimal
for most patients. However, pretreatment hepatic function
and the CTP score remains relevant and validated
prognostic factors of complications in HCC.
Dawson et al. published a risk analysis of the probability
of RILD using the Lyman NTCP model [19]. Their data
confirmed that the liver exhibits a large volume effect for
RILD, suggesting that the mean dose to the liver may
be useful for ranking radiation plans with twice-daily
fractions of 2 Gy. The dose-volume constraints usually
applied in the literature are summarized in Table 3.
Toxicities associated with SBRT for liver metastases
were minimal if conservative dose-volume constraints
for neighboring critical structures are respected for the
stomach and small intestine. Mendez Romero et al. re-
ported the following constraint: 5 cc of stomach should
receive less than 21 Gy [17]. Few series have reported
dose constraints to the heart, and a maximal dose of
7 Gy should be applied.
In 2001, the European Association for the Study of the
Liver (EASL) conference concluded that RECIST criteria
are not optimal to assess the response of liver tumors to
locoregional treatment [20]. Conversely, EASL recog-
nized that treatment-induced modifications in tumors
correlated well with alterations in contrast enhancement
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imaging reflect necrosis, whereas viable tumor remains
visible as a contrast-enhanced area. Therefore EASL cri-
teria were used to assess tumor response in the present
series. This is consistent with a previous report by Forner
and al: they applied RECIST and EASL criteria to two pro-
spective cohorts that had been treated with transarterial
chemoembolization or percutaneous ablation for HCC
[21]. They concluded that RECIST missed all of the CR
and underestimated partial response compared with
EASL. Furthermore, they found no correlation between
EASL and RECIST and if RECIST criteria were used, then
the rate of initial objective response would have been
around 0%. Thus, the established efficacy of the treatment
would have been obscured.
In the most recent series of liver SBRT, EASL criteria
were used to assess tumor response. Price et al. reported
their experience of SBRT on 26 patients with HCC [22].
SBRT delivered 24 to 48 Gy. MRI was performed every
3 months after treatment. At 12 months, eighteen of
the 26 patients (69%) had more than 50% of non-
enhancement, among whom thirteen had 100% of non-
enhancement. However, only four patients had a complete
response according to RECIST at the same time point.
Peritumoral enhancement should not be regarded as
tumor progression and needs to be interpreted with cau-
tion. In the present series, imaging at 6 and 9 months dis-
tinguishes between progression and benign inflammation
lesions that were difficult to analyze at 3 months. A first
imaging evaluation at 6 months could be recommended.
Furthermore, patients assessed according to EASL criteria
have longer overall survival, thus justifying the use of
EASL guidelines in series reporting the clinical results of
local liver therapies for HCC.
Conclusion
An international survey on radiotherapy for liver metas-
tases suggests that radiation oncologists will be seeing
more referrals for liver radiotherapy [23].
For HCC, SBRT with IGRT alone or combined with
other loco-regional treatment such as Trans Arterial
Chemo-Embolization (TACE) may play a significant role
in the treatment of unresectable HCC.
Prospective studies are now needed to compare regimens
and to identify parameters in order to optimize patient
selection.
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